Tag: Respiratory Problems: Misc.

Findings seen in phase 3 trial of adults aged 60 years and older receiving a single intramuscular injection of RSVpreF vaccine

Phase 3 trial shows the vaccine is effective against medically attended severe RSV-associated lower respiratory tract illness in infants

However, evidence shows the 2022 to 2023 season is a return toward prepandemic seasonality

Black patients experience younger age for first hospitalization, lung transplant, and death

Those with lower respiratory tract infection during early childhood have increased risk for dying from respiratory disease by age 73 years

Decreased functional residual capacity and increased respiratory rate seen with long-term heat and cold exposure for female newborns

Pulmonary function tests may be beneficial every six months, may be of use in initiating noninvasive ventilation when indicated

Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo

In two-part vote, panel voted 10 to 2 in favor of the vaccine's safety and unanimously on the shot's effectiveness

Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86 percent